Maternal therapy for HIV in pregnancy

Clinical Obstetrics and Gynecology

Volumn 44, Issue 2, 2001, Pages 182-197

  Watts, D Heather ^a  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ACICLOVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; ATOVAQUONE; AZITHROMYCIN; COTRIMOXAZOLE; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; FAMCICLOVIR; FLUCONAZOLE; HYDROXYUREA; INDINAVIR; ITRACONAZOLE; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; PENTAMIDINE; PROTEINASE INHIBITOR; PYRAZINAMIDE; RIFAMPICIN; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; UNINDEXED DRUG; VALACICLOVIR; ZALCITABINE; ZIDOVUDINE;

BONE MARROW SUPPRESSION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY DISEASE; NEUROPATHY; NEUROTOXICITY; OPPORTUNISTIC INFECTION; PANCREATITIS; PREGNANCY COMPLICATION; RASH; REVIEW; TREATMENT PLANNING;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; FEMALE; HIV INFECTIONS; HUMANS; POSTNATAL CARE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; VACCINATION;

EID: 0035041205     PISSN: 00099201     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003081-200106000-00008     Document Type: Review

References (23)

1. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment: Pediatric AIDS clinical trials group protocol 076 study group
2. USPHS task force recommendations for the use of antiretroviral drugs in pregnant women infected with HIV-1 for maternal health and for reducing perinatal HIV-1 transmission in the United States
3. Report of the NIH panel to define principles of therapy of HIV infection and guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents
4. Antiretroviral therapy in adults: Updated recommendations of the international AIDS society-USA panel
5. Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine
6. Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission
7. Rapid development of genotypic resistance to lamivudine when combined with zidovudine in pregnancy
8. Nonclinical toxicology studies with zidovudine: Genetic toxicity tests and carcinogenicity bioassays in mice and rates
9. Transplacental effects of 3′-azido-2'3′-dideoxythymidine (AZT): Tumorigenicity in mice and genotoxicity in mice and monkeys
10. A transplacental carcinogenicity bioassay in CD-1 mice with zidovudine
11. Using 3′-azido'2'3′-dideoxythmidine (AZT) to prevent perinatal human immunodeficiency virus transmission and risk of transplacental carcinogenesis
12. Lack of tumors in infants with perinatal HIV-1 exposure and fetal/neonatal exposure to zidovudine
13. Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues
14. Ongoing nucleoside safety review of HIV-exposed children in the US studies
15. Lack of long-term effects of in utero exposure to zidovudine among uninfected children born to HIV-infected women
16. Review of neurologic adverse events in relation to mitochondrial dysfunction in the prevention of mother to child transmission of HIV: PETRA study
17. Is zidovudine therapy in pregnant HIV-infected women associated with gestational age and birthweight?
18. Antiretroviral therapies in pregnancy: Maternal, fetal and neonatal effects
19. Drug-resistance genotyping in HIV-1 therapy: The VIRADAPT randomised controlled trial
20. A pilot study of the short-term effects of antiretroviral management based on plasma genotypic antiretroviral resistance testing (GART) in patients failing antiretroviral therapy
21. Phenotypic resistance testing significantly improves response to therapy: A randomized trial (VIRA3001)
22. 1999 USPHS/IDSA guidelines for the prevention of opportunistic infection in persons infected with human immunodeficiency virus: US Public Health Service (USPHS) and Infectious Diseases Society of America (IDSA)
23. Prevention and control of influenza: Recommendations of the Advisory Committee on Immunization Practices (ACIP)